Visitors Now:
Total Visits:
Total Stories:
Profile image
Story Views

Last Hour:
Last 24 Hours:

Celiac Disease Treatment Pipeline Review H2 2016

Friday, October 14, 2016 5:32
% of readers think this story is Fact. Add your two cents.

(Before It's News)


‘Celiac Disease – Pipeline Review, H2 2016’, provides an overview of the Celiac Disease pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Celiac Disease, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Celiac Disease and features dormant and discontinued projects.

Request a sample report @

Report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.


- The report provides a snapshot of the global therapeutic landscape of Celiac Disease 
- The report reviews pipeline therapeutics for Celiac Disease by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved Celiac Disease therapeutics and enlists all their major and minor projects 
- The report assesses Celiac Disease therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news related to pipeline therapeutics for Celiac Disease

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies 
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand important and diverse types of therapeutics under development for Celiac Disease 
- Identify potential new clients or partners in the target demographic 
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics 
- Devise corrective measures for pipeline projects by understanding Celiac Disease pipeline depth and focus of Indication therapeutics 
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope 
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Make an enquiry before buying this Report @

Key points in table of content

Table of Contents 2 
List of Tables 6 
List of Figures 7 
Introduction 8 
Global Markets Direct Report Coverage 8 
Celiac Disease Overview 9 
Therapeutics Development 10 
Pipeline Products for Celiac Disease – Overview 10 
Pipeline Products for Celiac Disease – Comparative Analysis 11 
Celiac Disease – Therapeutics under Development by Companies 12 
Celiac Disease – Therapeutics under Investigation by Universities/Institutes 14 
Celiac Disease – Pipeline Products Glance 15 
Clinical Stage Products 15 
Early Stage Products 16 
Celiac Disease – Products under Development by Companies 17 
Celiac Disease – Products under Investigation by Universities/Institutes 18 
Celiac Disease – Companies Involved in Therapeutics Development 19 
Amgen Inc. 19 
Amyra Biotech AG 20 
Avaxia Biologics, Inc. 21 
Calypso Biotech SA 22 
enGene, Inc 23 
F. Hoffmann-La Roche Ltd. 24 
Glenmark Pharmaceuticals Ltd. 25 
ImmusanT, Inc. 26 
Innovate Biopharmaceuticals, Inc. 27 
Intrexon Corporation 28 
Sanofi 29 
Zedira GmbH 30 
Celiac Disease – Therapeutics Assessment 31 
Assessment by Monotherapy Products 31 
Assessment by Target 32 
Assessment by Mechanism of Action 34 
Assessment by Route of Administration 36 
Assessment by Molecule Type 38 
Drug Profiles 40 
AMG-714 – Drug Profile 40 
Product Description 40 
Mechanism Of Action 40 
R&D Progress 40 
AVX-176 – Drug Profile 42 
Product Description 42 
Mechanism Of Action 42 
R&D Progress 42 
Biologic for Celiac Disease – Drug Profile 43 
Product Description 43 
Mechanism Of Action 43 
R&D Progress 43 
BNZ-2 – Drug Profile 44 
Product Description 44 
Mechanism Of Action 44 
R&D Progress 44 
CALY-002 – Drug Profile 45 
Product Description 45 
Mechanism Of Action 45 
R&D Progress 45 
ERW-1041E – Drug Profile 46 
Product Description 46 
Mechanism Of Action 46 
R&D Progress 46 
GBR-830 – Drug Profile 47 
Product Description 47 
Mechanism Of Action 47 
R&D Progress 47 
larazotide acetate – Drug Profile 48 
Product Description 48 
Mechanism Of Action 48 
R&D Progress 48 
latiglutenase – Drug Profile 50 
Product Description 50 
Mechanism Of Action 50 
R&D Progress 50 
Monoclonal Antibody to Antagonize IL-2R Beta for Celiac Disease, Central Nervous System and Oncology – Drug Profile 53 
Product Description 53 
Mechanism Of Action 53 
R&D Progress 53 
Nexvax-2 – Drug Profile 54 
Product Description 54 
Mechanism Of Action 54 
R&D Progress 54 
Nexvax-3 – Drug Profile 57 
Product Description 57 
Mechanism Of Action 57 
R&D Progress 57 
Oligonucleotides for Celiac Disease – Drug Profile 58 
Product Description 58 
Mechanism Of Action 58 
R&D Progress 58 
Protein for Celiac Disease – Drug Profile 59 
Product Description 59 
Mechanism Of Action 59 
R&D Progress 59 
Recombinant Enzymes for Celiac Disease – Drug Profile 60 
Product Description 60 
Mechanism Of Action 60 
R&D Progress 60 
Recombinant Protein for Celiac Disease and Type-1 Diabetes – Drug Profile 61 
Product Description 61 
Mechanism Of Action 61 
R&D Progress 61 
RG-7625 – Drug Profile 62 
Product Description 62 
Mechanism Of Action 62 
R&D Progress 62 
Synthetic Peptides to Inhibit DQ2/DQ8 for Celiac Disease and Type 1 Diabetes – Drug Profile 63 
Product Description 63 
Mechanism Of Action 63 
R&D Progress 63 
Vaccine for Celiac Disease – Drug Profile 64 
Product Description 64 
Mechanism Of Action 64 
R&D Progress 64 
Vaccine for Celiac Disease – Drug Profile 65 
Product Description 65 
Mechanism Of Action 65 
R&D Progress 65 
ZED-1227 – Drug Profile 66 
Product Description 66 
Mechanism Of Action 66 
R&D Progress 66 
ZED-754 – Drug Profile 67 
Product Description 67 
Mechanism Of Action 67 
R&D Progress 67 
Celiac Disease – Dormant Projects 68 
Celiac Disease – Product Development Milestones 69 
Featured News & Press Releases 69 
May 24, 2016: ImmusanT Reports Nexvax2 Phase 1 Data in Patients with Celiac Disease 69 
May 19, 2016: ImmusanT Announces Presentations at Digestive Disease Week 2016 70 
May 05, 2016: Celimmune Commences First-Ever Dosing with AMG 714 in Celiac Disease 71 
Mar 31, 2016: Celimmune Commences Screening in Phase 2 Clinical Study in Refractory Celiac Disease Type II 72 
Sep 23, 2015: Celimmune to Present Overview of Non-Dietary Celiac Disease Therapies in Development at Annual Celiac Support Association Meeting 73 
Sep 03, 2015: Glenmark’s Novel Monoclonal Antibody GBR 830 to Enter Phase 2 Clinical Studies in Atopic Dermatitis and Celiac Disease in US and Europe 73 
Jun 22, 2015: Celimmune to Present Experimental Anti3IL315 Antibody AMG!714 at 16th International Coeliac Disease Symposium 74 
Jun 22, 2015: Cour Pharmaceuticals Releases Data on Potential Breakthrough Treatment for Celiac Disease 74 
Nov 19, 2014: ImmusanT’s Immunotherapy for Celiac Disease, Nexvax2, Selected as One of Informa’s Top 10 Autoimmune/Anti-Inflammatory Projects to Watch 75 
Jun 12, 2014: Potential New Treatment May Protect Celiac Patients from Gluten-Induced Injury 76 
Feb 11, 2014: Alba Therapeutics Announces Positive Results of Phase IIb Trial in Celiac Disease 76 
Oct 29, 2013: Alvine Pharmaceuticals Doses First Patient in Phase 2b Trial for ALV003 in Celiac Disease 77 
Aug 06, 2013: ImmusanT Initiates Study at Joslin Diabetes Center to Investigate Relationship Between Celiac Disease and Type 1 Diabetes 78 
Apr 19, 2013: ImmusanT’s Epitope-specific Immunotherapy For Celiac Disease Informs Potential Of Vaccines Against Other Autoimmune Diseases 78 
Sep 05, 2012: Alvine Pharma’s ALV003 Receives Fast Track Designation From FDA For Treatment Of Celiac Disease 79 
Appendix 81 
Methodology 81 
Coverage 81 
Secondary Research 81 
Primary Research 81 
Expert Panel Validation 81 
Contact Us 81 
Disclaimer 82

List of Tables 
Number of Products under Development for Celiac Disease, H2 2016 10 
Number of Products under Development for Celiac Disease – Comparative Analysis, H2 2016 11 
Number of Products under Development by Companies, H2 2016 13 
Number of Products under Investigation by Universities/Institutes, H2 2016 14 
Comparative Analysis by Clinical Stage Development, H2 2016 15 
Comparative Analysis by Early Stage Development, H2 2016 16 
Products under Development by Companies, H2 2016 17 
Products under Investigation by Universities/Institutes, H2 2016 18 
Celiac Disease – Pipeline by Amgen Inc., H2 2016 19 
Celiac Disease – Pipeline by Amyra Biotech AG, H2 2016 20 
Celiac Disease – Pipeline by Avaxia Biologics, Inc., H2 2016 21 
Celiac Disease – Pipeline by Calypso Biotech SA, H2 2016 22 
Celiac Disease – Pipeline by enGene, Inc, H2 2016 23 
Celiac Disease – Pipeline by F. Hoffmann-La Roche Ltd., H2 2016 24 
Celiac Disease – Pipeline by Glenmark Pharmaceuticals Ltd., H2 2016 25 
Celiac Disease – Pipeline by ImmusanT, Inc., H2 2016 26 
Celiac Disease – Pipeline by Innovate Biopharmaceuticals, Inc., H2 2016 27 
Celiac Disease – Pipeline by Intrexon Corporation, H2 2016 28 
Celiac Disease – Pipeline by Sanofi, H2 2016 29 
Celiac Disease – Pipeline by Zedira GmbH, H2 2016 30 
Assessment by Monotherapy Products, H2 2016 31 
Number of Products by Stage and Target, H2 2016 33 
Number of Products by Stage and Mechanism of Action, H2 2016 35 
Number of Products by Stage and Route of Administration, H2 2016 37 
Number of Products by Stage and Molecule Type, H2 2016 39 
Celiac Disease – Dormant Projects, H2 2016 68

Get this report @


Contact US:


Partner Relations & Marketing Manager

Ph: +1-646-845-9349 (US)

Ph: +44 208 133 9349 (UK)           

Report abuse


Your Comments
Question   Razz  Sad   Evil  Exclaim  Smile  Redface  Biggrin  Surprised  Eek   Confused   Cool  LOL   Mad   Twisted  Rolleyes   Wink  Idea  Arrow  Neutral  Cry   Mr. Green

Top Stories
Recent Stories



Email this story
Email this story

If you really want to ban this commenter, please write down the reason:

If you really want to disable all recommended stories, click on OK button. After that, you will be redirect to your options page.